Healthcare News 4 November 2025

Oracle’s ‘Truly Awesome’ AI Cloud Quarter Sends Stock Soaring 36%, Making Ellison World’s Richest

Oracle Stock Today, November 20, 2025: ORCL Slides as AI Debt Jitters Offset Health-Care Wins

Oracle Corporation (NYSE: ORCL) shares were under pressure on Thursday, November 20, 2025, as growing concerns over the company’s AI‑driven debt load and rising credit risk overshadowed a string of positive announcements in its healthcare and defense businesses. By late

20 November 2025

Artificial Intelligence·Financial News·Healthcare·Oracle·Stock Market

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion

20 November 2025

Cancer Research·Healthcare·Medical Technology·Mergers & Acquisitions·Stock Market News

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal

20 November 2025

Business News·Cancer Research·Healthcare·Medical Technology·Mergers & Acquisitions

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire cancer diagnostics specialist Exact Sciences, in what could be the healthcare giant’s largest deal in nearly a decade and a major shake-up for the global cancer testing market. Bloomberg Abbott in Talks

19 November 2025

Cancer Research·Healthcare·Medical Technology·Mergers & Acquisitions·Stock Market

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss

17 November 2025

Business News·Drug Pricing·Healthcare·Pharma Industry·Stock Market

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the

15 November 2025

Financial Results·Healthcare·Market Trends·Pharmaceuticals·Stock Analysis

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY)

14 November 2025

Financial Analysis·Healthcare·Investment News·Pharmaceuticals·Stock Market

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial

13 November 2025

Biotechnology·Clinical Trials·Healthcare·Investment News·Stock Market

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc. (NASDAQ: MGRX), the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official

13 November 2025

Business News·Healthcare·Pharmaceuticals·Stock Market

Scott Bessent Faces Fresh Scrutiny Over Medicare‑Tax ‘Limited Partner’ Loophole and an Unkept Back‑Taxes Pledge — What’s New on Nov. 12, 2025

Treasury Secretary Scott Bessent is back under the microscope over his past use of a Medicare self‑employment tax loophole commonly claimed by hedge‑fund managers and other partnership owners. Senate Democrats have alleged since January that Bessent avoided roughly $900,000 in

12 November 2025

Finance·Healthcare·Legal Issues

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and

6 November 2025

Drug Pricing·Healthcare·Pharmaceuticals

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the day Stockanalysis. This modest dip came amid a broader mixed market and ahead of the

4 November 2025

Company News·Financial Analysis·Healthcare·Investing·Stock Market

Healthcare News 4 November 2025 - 20 November 2025